{
    "nctId": "NCT01652560",
    "briefTitle": "Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy",
    "officialTitle": "Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Bevacizumab, Neoadjuvant Chemotherapy, Molecular Targeted Therapy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Objective Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2-negative breast cancer patients\n* Without surgery\n* Plans to neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* HER2-positive breast cancer patients\n* Post-operative patients",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}